Lorcaserin in obesity: minimal benefits and ill-defined harms
A recent lorcaserin trial investigated ‘the long-term cardiovascular and metabolic safety and efficacy of lorcaserin’ in subjects at high cardiovascular risk. The large number of exclusions, the minimal weight reductions observed and the selective reporting of harms leave major uncertainties about l...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019
|